The Institut Pasteur in Dakar acquires a latest-generation sequencer for genomic monitoring of SARS-CoV-2 variants and other emerging pathogens.

The Institut Pasteur in Dakar acquires a latest-generation sequencer for genomic monitoring of SARS-CoV-2 variants and other emerging pathogens.

Designated by the World Health Organization and the Africa Centers for Disease Control and Prevention (Africa CDC) as a reference laboratory for COVID-19, the Institut Pasteur in Dakar also provides genomic surveillance for SARS-CoV-2. both at national and sub-regional level. The institute was thus able to identify on December 5, 2021 the first two cases of infection with the Omicron variant in West Africa.

In the context of the circulation and emergence of worrying variants of SARS-CoV-2, with the financial support of the AFROSCREEN project, the Institut Pasteur in Dakar has acquired an Illumina NovaSeq 6000 sequencer. This next-generation sequencer, the most powerful in the Illumina line, offers breakthrough technological innovations providing unparalleled throughput, speed and reliability as well as adaptability to different scientific and public health needs.

Designated by the World Health Organization and the Africa Centers for Disease Control and Prevention (Africa CDC) as a reference laboratory for COVID-19, the Institut Pasteur in Dakar also provides genomic surveillance for SARS-CoV-2. both at national and sub-regional level. The institute was thus able to identify on December 5, 2021 the first two cases of infection with the Omicron variant in West Africa.

In the context of the circulation and emergence of worrying variants of SARS-CoV-2, with the financial support of the AFROSCREEN project, the Institut Pasteur in Dakar has acquired an Illumina NovaSeq 6000 sequencer. This next-generation sequencer, the most powerful in the Illumina line, offers breakthrough technological innovations providing unparalleled throughput, speed and reliability as well as adaptability to different scientific and public health needs.

Back to news